XeriSol glucagon
Phase 1Completed 0 watching 0 views this week💤 Quiet
28
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Type1diabetes
Conditions
Type1diabetes
Trial Timeline
Mar 29, 2018 → May 17, 2019
NCT ID
NCT03424044About XeriSol glucagon
XeriSol glucagon is a phase 1 stage product being developed by Xeris Pharmaceuticals for Type1diabetes. The current trial status is completed. This product is registered under clinical trial identifier NCT03424044. Target conditions include Type1diabetes.
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03424044 | Phase 1 | Completed |
Competing Products
2 competing products in Type1diabetes
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Dapagliflozin + Placebo Oral Tablet | AstraZeneca | Phase 1 | 33 |
| UP421 | Sana Biotechnology | Phase 1 | 28 |